NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,683,492 | -58.7% | 1,573,357 | 0.0% | 0.38% | -50.3% |
| Q2 2023 | $4,074,995 | -48.4% | 1,573,357 | 0.0% | 0.75% | -48.6% |
| Q1 2023 | $7,898,252 | 0.0% | 1,573,357 | 0.0% | 1.47% | +42.5% |
| Q4 2022 | $7,898,252 | -61.6% | 1,573,357 | 0.0% | 1.03% | -64.8% |
| Q3 2022 | $20,580,000 | +2.0% | 1,573,357 | 0.0% | 2.93% | +35.7% |
| Q2 2022 | $20,170,000 | -15.9% | 1,573,357 | 0.0% | 2.16% | +20.6% |
| Q1 2022 | $23,994,000 | -13.9% | 1,573,357 | 0.0% | 1.79% | +12.7% |
| Q4 2021 | $27,864,000 | -15.7% | 1,573,357 | 0.0% | 1.59% | -25.9% |
| Q3 2021 | $33,072,000 | – | 1,573,357 | – | 2.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |